Table 3.
The performance of MS-based urine tests for the detection of adenomatous polyp on both training set and testing set, along with the performance of three fecal based tests. When picking a threshold on the training set, the performance on the testing set with the same threshold produces similar performance.
| Training Set | Testing Set | |||||||
|---|---|---|---|---|---|---|---|---|
| Threshold Criteria | Sensitivity | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV |
| Urine tests | ||||||||
| Sens = 90% (95% CI *) |
90.3% (84.6–96.0%) |
20.9% (16.7–25.1%) |
24.9% | 88.0% | 92.2% (84.8–99.5%) |
19.2% (13.3–25.1%) |
25.3% | 89.2% |
| Sens = 80% (95% CI) |
79.6% (71.8–87.4%) |
42.1% (36.9–47.2%) |
28.6% | 87.7% |
82.4% (71.9–92.8%) |
36.0% (28.9–43.2%) |
27.6% | 87.3% |
| Sens = 70% (95% CI) |
69.9% (61.0–78.8%) |
59.0% (53.9–64.2%) |
33.2% | 87.1% | 66.7% (53.7–79.6%) |
55.2% (47.8–62.7%) |
30.6% | 84.8% |
| Spec = 70% (95% CI) |
59.2% (49.7–68.7%) |
70.1% (65.3–74.8%) |
36.5% | 85.5% | 56.9% (43.3–70.5%) |
70.9% (64.1–77.4%) |
35.4% | 84.7% |
| Spec = 80% (95% CI) |
46.6% (37.2–56.2%) |
80.0% (75.8–84.1%) |
40.3% | 83.7% | 49.0% (35.3–62.7%) |
80.8% (74.9–86.7%) |
43.1% | 84.2% |
| Spec = 90% (95% CI) |
31.1% (22.1–40.0%) |
88.1% (84.8–91.5%) |
43.2% | 81.4% |
43.1% (29.5–56.7%) |
91.3% (87.1–95.5%) |
59.5% | 84.4% |
| Fecal Tests | ||||||||
| Guaiac HemII | 2.0% | 98.8% | 33.3% | 77.5% | 3.8% | 99.4% | 66.7% | 77.1% |
| Immune ICT | 10.9% | 97.1% | 52.4% | 78.7% | 17.6% | 97.0% | 64.3% | 79.6% |
| Immune MagSt | 15.8% | 95.4% | 50.0% | 79.5% | 21.2% | 91.7% | 44.0% | 79.1% |
* CI: confidence intervals. They were estimated based on based on binomial distribution.